Table 3.
Multivariable analyses of overall survival and progression-free survival in patients with available pre-treatment C-reactive protein-to-albumin ratio data.
| OS | PFS | |||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | p | HR | (95% CI) | p | |
| Age > 60 years | 2.91 | (1.05–8.07) | 0.040 | 1.90 | (0.93–3.89) | 0.080 |
| Stage (III, IV) | 2.15 | (0.54–8.57) | 0.278 | 2.52 | (1.00–6.36) | 0.050 |
| LDH > UNL | 1.77 | (0.34–9.19) | 0.499 | 1.16 | (0.44–3.05) | 0.769 |
| ECOG PS > 1 | 1.96 | (0.77–4.97) | 0.158 | 1.81 | (0.85–3.84) | 0.124 |
| EN > 1 | 1.26 | (0.48–3.35) | 0.637 | 0.96 | (0.46–1.98) | 0.908 |
| CAR > 0.158 | 6.02 | (1.19–30.38) | 0.030 | 3.62 | (1.40–9.36) | 0.008 |
| IPI ≥ 3 | 8.97 | (1.93–41.63) | 0.005 | 3.17 | (1.43–7.00) | 0.004 |
| CAR > 0.158 | 4.35 | (0.94–20.15) | 0.060 | 3.35 | (1.36–8.20) | 0.008 |
OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, UNL upper normal limit, ECOG PS Eastern Cooperative Oncology Group performance status, EN extranodal, CAR C-reactive protein-to-albumin ratio, IPI international prognostic index.